drugset / Trial / NCT04910594
Clinical Study the Efficacy and Safety of Rh-EPO in the Treatment of Anemia in Lymphoma
Phase 3
Unknown
130 enrolled
Second Affiliated Hospital, School of Medicine, Zhejiang University
Affiliated Hospital of Jiaxing University · collabFirst Affiliated Hospital of Wenzhou Medical University · collabFirst People's Hospital of Hangzhou · collabNingbo Medical Center Lihuili Hospital · collabSecond Affiliated Hospital of Wenzhou Medical University · collabTaizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University · collabThe First Affiliated Hospital of Zhejiang Chinese Medical University · collabWenzhou Central Hospital · collabZhejiang Cancer Hospital · collabZhejiang Provincial Tongde Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
The incidence of lymphoma and anemia is high and the clinical harm is great.However, it has not yet attracted enough clinical attention, and domestic rHuEPO (trade name: Ebio).Shenyang Sansheng Pharmaceutical Co., Ltd.) for lymphoma and anemia patients are less clinical studies.Therefore, a prospective, open-label, multicenter clinical study of recombinant human erythropoietin in the treatment of anemia in patients with lymphoma is planned to analyze the efficacy and safety of recombinant human erythropoietin in patients with lymphoma and anemia, so as to determine the clinical benefits of recombinant human erythropoietin in patients with lymphoma and anemia.
Timeline
- Start
- 2021-04-01
- Primary completion
- 2023-02-14
- Completion
- 2023-04-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | epoetin alfa | Protein / enzyme biologic | — | — |